APA Alerts Flashcards
FDA Approves First Once-Monthly Injectable Buprenorphine for Opioid Use Disorder
Sublocade (Indivdor Inc.)
tx of OUD in adults who have initiated treatment with a transmucosal (absorbed through mucus membrane) buprenorphine-containing product
indicated for patients who have been on a stable dose of buprenorphine treatment for a minimum of 7 days
Sublocade SEs
constipation, nausea, vomiting, headache, drowsiness, injection site pain, itching (pruritus) at the injection site, and abnormal liver function tests.
not studied in patients under 17 years or over age of 65.
Sublocade boxed warning
dangers of administering the drug IV instead of subQ- forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including threatening pulmonary emboli
As many as a third (32.2%) of all patients with ? may go on to develop schizophrenia or bipolar disorder within five years
substance use-induced psychosis
the highest risk of conversion was for patients who experienced cannabis-induced psychosis, which had a conversion rate of 47.4%
highest risk of conversion to schizophrenia for those 16 to 25 years
Long-Term SSRI Treatment May Delay Progression From Mild Cognitive Impairment to Alzheimer’s Dementia
a significantly decreased probability of conversion to Alzheimer’s dementia in MCI patients with a history of depression and long-term SSRI treatment [>1,610 days] compared with all other groups,
Cannabidiol May Be Effective Adjunct to Antipsychotic Treatment for Schizophrenia Patient
Patients with schizophrenia who are prescribed cannabidiol (CBD) in addition to antipsychotics may experience lower levels of positive psychotic symptoms compared with those taking antipsychotics alone, may also improve cognitive performance and overall functioning.
Adjunctive Ketamine Appears to Reduce Suicidal Thoughts in Depressed Patients for Up to Six Weeks
Within 24 hours of IV ketamine (0.5 mg/kg in 100 mL saline) or midazolam (0.02 mg/kg in 100 mL saline) infused over 40 minutes, patients in the ketamine group experienced a greater reduction in SSI score : 55% for the ketamine group and 30% for the midazolam group
Catatonia Often Goes Undiagnosed, Untreated in General Hospitals
- often reversible when treated with lorazepam and/or electroconvulsive therapy (ECT)
- failure to recognize may lead to improper treatment with antipsychotics, which can increase the risk for developing malignant catatonic features or NMS
- presence of grimacing, agitation, or echolalia symptoms was associated with a 4 to 6 times greater likelihood that the catatonia would go undiagnosed
First Non-Opioid Medication Approved to Reduce Opioid Withdrawal Symptoms in Adults
Lucemyra—an oral, selective alpha 2-adrenergic receptor agonist—is approved for treatment up to 14 days.
can reduce anxiety, agitation, drug craving, muscle aches, sleep problems, stomach cramps, and more
what can reduce symptoms and improve quality of life for patients recently diagnosed with psychosis
early intervention programs or coordinated specialty care (CSC) program
- experienced significant improvements in health, function, and education/employment within months,
medication May Decrease Symptoms Of Moderate And Severe PPD
brexanolone, an intravenous (IV) formulation of allopregnanolone, neuroactive steroid
- administered as a single, continuous IV infusion for 60 hours
- benefit of treatment persisted at the 30-day follow-up assessment
regimen for PPD
antidepressant:
paroxetine (paxil) or sertraline (zoloft)- low levels found in infants exposed to breast milk
Escitalopram, fluoxetine, and fluvoxamine are used less often
plus add-on treatment with drugs such as second-generation antipsychotics, lithium, or triiodothyronine.
resistant PPD
switch antidepressants rather than augmentation with a second drug: another SSRI, a serotonin-norepinephrine reuptake inhibitor (eg, desvenlafaxine, duloxetine, or venlafaxine), an atypical antidepressant (bupropion or mirtazapine), or a tricyclic (eg, nortriptyline)
partial response to PPD treatment
add on 2nd drug rather than switch:
second-generation antipsychotics (eg, aripiprazole, risperidone, or olanzapine), lithium, and triiodothyronine
hormonal tx in PPD
- progestin (single norethisterone 200 mg injection) and placebo were comparable
- estrogen (transdermal 17 beta-estrogen 200 mg/day plus cyclical dydrogesterone) with placebo; improvement was greater with estrogen than placebo.
the FDA has approved the first generic version of Suboxone
(buprenorphine and naloxone) “film strip that dissolves under the tongue”